The ZNF217 Biomarker Predicts Low- And High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2019.00524
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

Oncotype Dx Recurrence Score Among BRCA1/2 Germline Mutation Carriers With Hormone Receptors Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Treatment Decisions in Estrogen Receptor-Positive Early Breast Cancer Patients With Intermediate Oncotype DX Recurrence Score Results

SpringerPlus
Multidisciplinary
2014English

Oncotype DX Breast Cancer Recurrence Score Resists Inter-Assay Reproducibility With RT2-Profiler Multiplex RT-PCR

Scientific Reports
Multidisciplinary
2019English

The Impact of Oncotype DX® Recurrence Score of Paraffin-Embedded Core Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in Women With Breast Cancer

Breast Disease
MedicineCancer ResearchOncology
2016English

Evaluation and Correlation of Risk Recurrence in Early Breast Cancer Assessed by Oncotype DX®, Clinicopathological Markers and Tumor Cell Dissemination in the Blood and Bone Marrow

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age

Advances in Therapy
MedicinePharmacology
2015English

A Weighted Genetic Risk Score Predicts Surgical Recurrence Independent of High-Risk Clinical Features in Dupuytren’s Disease

Plastic and Reconstructive Surgery
Surgery
2019English

Oncotype Dx® in the Sistema Único De Saúde Do Brasil (Sus): Result of 125 Cases

2019English

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy